Share

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

Recent Publications

A Simple, Ultrastable, and Cost-Effective Oxygen-Scavenging System for Long-Term DNA-PAINT Imaging

Published On 2025 Dec 19

Journal article

DNA-PAINT (Points Accumulation in Nanoscale Topography) is a super-resolution microscopy technique capable of nanoscale imaging through the transient binding of fluorescently labeled imager strands to complementary DNA docking strands. Imager strands can be continuously replenished from an effectively infinite pool, making DNA-PAINT inherently resistant to photobleaching. However, extended DNA-PAINT imaging is limited by the formation of reactive oxygen species (ROS), which damage docking...


Engineered base editors with reduced bystander editing through directed evolution

Published On 2025 Dec 18

Journal article

Base editors enable precise genome modification but are constrained by bystander edits that limit their applicability. Existing strategies to enhance precision often compromise efficiency and remain highly sequence dependent. Here we present a parallel engineering approach that optimizes both guide RNAs and the deaminase enzyme to minimize bystander editing without sacrificing activity. We designed a library of 3'-extended guide RNAs and identified context-dependent variants that improved...